PTC/SBAGEs (08-03.)
Approved for use through 07/31/2008, OMB 0851-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are sequired to respond to a collection of information unless it contains a valid DMB control number.

U.S.PATENTS

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10534770			
Filing Date		2005-05-13			
First Named Inventor Shing		go Kawai			
Art Unit		2829			
Examiner Name					
Attorney Docket Number		85367			

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	issue C	ate	Name of Pat of cited Door	entee or Applicant ument	Rele	es,Columns,Lines when vant Passages or Releves res Appear	
	1	5185643	A	1993-02	-09	Vry et al.				
	2	6104526	A	2000-08	-15	Kakui				
	3	6393041	В1	2002-05	i-21	Sato				
If you wish	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.			
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS			
Examiner Initial*						es,Columns,Lines where vant Passages or Relev res Appear				
	1									
If you wish	n to ac	dd additional U.S. Publi	shed Ap	plication	citation	n information	please click the Ad	d butte	on.	
				FOREIG	SN PAT	TENT DOCUM	IENTS			
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T6
	1	1156563	EP		A2	2001-11-21	Hitachi, Ltd.			

Application Number 10534770 Filing Date 2005-05-13 INFORMATION DISCLOSURE First Named Inventor Shingo Kawai STATEMENT BY APPLICANT Art Unit 2829 (Not for submission under 37 CFR 1.99) Examiner Name Attorney Docket Number 85367

	2	1345296	EP	A1	2003-09-17	Agilent Technologies, Inc.		
	3	2006039530	wo	A2	2006-04-13	Broadband Royalty Corporation		
If you wist	h to a	d additional Foreign Pa	atent Document	citation	information pl	ease click the Add buttor	1	

NON-PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), tille of the Item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5				
	1						

1							
If you wish to add ad	If you wish to add additional non-patent literature document citation information please click the Add button						
EXAMINER SIGNATURE							
Examiner Signature	Date Considered		\neg				
*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GCV or MIPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the seriel number of the potent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, 5 Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit

Application Number		10534770			
Filing Date		2005-05-13			
First Named Inventor	Shing	go Kawai			
Art Unit		2829			
Examiner Name	Ι				
Attack on Destant March on		0.0003			

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication form a foreign patient office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97[e/17].

OR

That no item of Information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.39(file).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted berewith.

E No

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

 Signature
 Date (YYYY-MM-DD)
 2007-01-11

 Name/Print
 Lilia I. Safonov
 Registration Number
 45967

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fault by the LSPTO to process) an application. Confidentially is governed by \$5.1.S.C. 122 and \$7.CFR.

1.14. This collection is estimated to take if hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operationed for Commence, P.O. 8bs 1450, Alexandric, V.S. 2251.1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandric, V.S. 2251.1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-79) requires that you be given contain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is \$3 U.S.C. (2)(2)(2) (2) lumishing of the information solicide that: (1) the general authority for the collection of this information is \$3 U.S.C. (2)(2)(2)(2) (2) lumishing of the information solicide to exclusive and of the privacy of the solicide that is a collection of the patient of the desired to the solicide of the

The information provided by you in this form will be subject to the following routine uses:

- The Information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to e court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting e request involving an Individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
- A record related to an International Application filed under the Patent Cooperation Treety in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an insepsetion of records conducted by GSA a part of that eponcy. Freepombility to recommend improvements in records management practices and programs, under eath-only of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall be made in accordance value.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as routine use, to the public if the record way find in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published accidation, an addication cover to publish expendence or an issuant patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.